Trial site

Assuta Ashdod Medical Center

Ashdod, Ashdod 7747629, IsraelNot linked to an institution yet

17running trials
1closed trial

The trials here

What the 18 trials at this site are about, from their registry records.

Conditions: Crohn's disease4 trials
Ulcerative colitis3 trials
COPD2 trials
Follicular lymphoma2 trials
Obesity2 trials
Chronic kidney disease1 trial
Chronic lymphocytic leukaemia1 trial
Coeliac disease1 trial
Diffuse large B-cell lymphoma1 trial
Mantle cell lymphoma1 trial
Multiple myeloma1 trial
Prostate cancer1 trial
and 3 more
Phase: Phase 38 trials
Phase 26 trials
Phase 1/21 trial
Phase 2/31 trial
Status: Active, not recruiting8 trials
Recruiting8 trials
Completed1 trial
Not yet recruiting1 trial
Lead sponsor: Eli Lilly and Company6 trials
BeOne Medicines3 trials
Karyopharm Therapeutics Inc2 trials
Takeda2 trials
BioProtect1 trial
and 4 more

Running trials

Recruiting
A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
NCT07483099· Phase 2· Eli Lilly and Company· Source
Contact: Adi Lahat-Zok (principal investigator)
Recruiting
A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
NCT07483073· Phase 2· Eli Lilly and Company· Source
Contact: Adi Lahat-Zok (principal investigator)
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· Phase 2· Eli Lilly and Company· Source
Contact: Adi Lahat-Zok (principal investigator)
Recruiting
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
NCT07241390· Phase 3· Eli Lilly and Company· Source
Contact: Yana Kakzanov (principal investigator)
Recruiting
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
NCT06937099· Phase 3· Eli Lilly and Company· Source
Contact: Adi Lahat-Zok (principal investigator)
Recruiting
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086· Phase 3· Eli Lilly and Company· Source
Contact: Adi Lahat-Zok (principal investigator)
Not yet recruiting
Iron Deficiency in Pediatric Celiac Disease: Diet vs. Iron Supplementation Trial
NCT06921343· Kaplan Medical Center· Source
Contact: Chani Topf-Olivestone, MD
Active, not recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· Phase 3· Takeda· Source
Recruiting
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461· Phase 2· Takeda· Source
Contact: Adi Lahat-Tzok (principal investigator)
Recruiting
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821· Phase 3· BeOne Medicines· Source
Active, not recruiting
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NCT05878769· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
NCT05471843· Phase 1/2· BeOne Medicines· Source
Active, not recruiting
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862· Phase 3· BeOne Medicines· Source
Active, not recruiting
Post Marketing Clinical Follow Up of the BioProtect Balloon Implant System
NCT05354440· BioProtect· Source
Active, not recruiting
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT04442022· Phase 2/3· Karyopharm Therapeutics Inc· Source
Recruiting
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.
NCT04414475· Phase 2· Karyopharm Therapeutics Inc· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Crohn's disease4 recruiting
Ulcerative colitis3 recruiting
Obesity2 recruiting
Chronic kidney disease1 recruiting
Coeliac disease1 recruiting
Follicular lymphoma1 recruiting
Stroke1 recruiting

Closed trials

Completed
A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05037929· Phase 2· Genentech, Inc.· Source

Site data: ClinicalTrials.govUpdated 14 Nov 2026

Report an error